Xenon Pharmaceuticals reported a commanding Phase 3 X‑Tole2 result for azetukalner in focal onset seizures, with placebo‑adjusted seizure reductions that far exceeded Wall Street forecasts. The company said the data support plans to submit an NDA in the third quarter and highlighted a favorable tolerability profile that positions azetukalner as an easy‑to‑use, once‑daily oral option. Market reaction was immediate: Xenon shares jumped sharply after the readout. Xenon’s CEO framed the result as the strongest placebo‑adjusted efficacy observed in a pivotal epilepsy study to date and emphasized the drug’s potential to become a standard‑of‑care agent given efficacy and dose‑dependent safety findings. Regulatory pathway: Xenon will translate the pivotal dataset into an FDA submission; reviewers will evaluate dose‑dependent adverse events and discontinuation rates at the higher dose. The readout also increases competitive pressure on other KV7 channel programs in late‑stage development.